Research Technician II/III Immunotherapy and Single Cell Profiling
Fred Hutchinson Cancer Research Center
Location: Seattle, Washington
Internal Number: 21236
Cures Start Here. At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutchs pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nations first cancer prevention research program, as well as the clinical coordinating center of the Womens Health Initiative and the international headquarters of the HIV Vaccine Trials Network. Careers Start Here.
At Fred Hutch, we believe that the innovation, collaboration, and rigor that result from diversity and inclusion are critical to our mission of eliminating cancer and related diseases. We seek employeeswho bringdifferent and innovativeways of seeing the world and solving problems.Fred Hutch is in pursuit of becoming an antiracist organization.Weare committed to ensuring that all candidates hired share our commitment to diversity,antiracism, and inclusion.
A research technician II/III position (full-time) is available immediately in a laboratory within Fred Hutchinson Cancer Research Centers Translational Research Program. The Laboratory for the Study of Metastatic Microenvironments focuses on understanding the biology underlying disseminated tumor cell (DTC) dormancy and formulating therapeutic means to eradicate dormant DTCs. We are looking for a dynamic, bright, meticulous, and highly motivated individual to join our team to help us profile human DTCs isolated from breast cancer patients in order to identify targets for immunotherapy.
The ideal candidate will have a strong interest in tumor metastasis, immunology, and translational research. They will be responsible for performing standard and investigative laboratory work, including: following detailed, time-sensitive protocols for processing breast cancer patient bone marrow, index sorting single disseminated tumor cells, following meticulous protocols to profile single DTC transcriptomes, and assisting with follow up experiments to test potential immunotherapeutic targets in experimental models.
This position will work under the Principal Investigator and work with fellows in the lab to carry out the following job duties:
Keep meticulous records on processed samples, storage conditions and data generated on a large human clinical study.
Adhere fastidiously to detailed protocols to process human bone marrow, index sort single DTCs, and perform single cell genomic preps.
Conduct immunohistochemistry and immunofluorescence on human tissue specimens.
Organize sequencing data for downstream processing.
Assist with follow up experiments in mice and in cell culture to test biologic and immunologic implications of human studies.
Perform statistical analyses to analyze resulting data
Perform other duties as required
Bachelors degree in cell biology, immunology, or related disciplines required
Research Techn II minimum qualifications- 2+ years of lab experience and must have scientific knowledge in the area of study and basic laboratory skills. At least one-year (and up to three years) of independent research experience in a laboratory setting (during undergraduate tenure okay)
Research Techn III minimum qualifications- Senior level position requiring extensive experience in a laboratory
Experience with mammalian cell culture and mouse handling
Experience with Flow Cytometry and single cell genomics is highly preferred
The ideal candidate will be meticulous, self-driven, enthusiastic, highly-organized, and excited to participate in this critical work
Experience with flow cytometry and genomic approaches is a definite bonus
Fred Hutch has a mandatory COVID-19 vaccine requirement, with exceptions only for approved medical or religious accommodations. As a condition of employment, newly hired employees must provide proof of vaccination or initiate the accommodations process before their first day of employment.
A statement describing your commitment and contributions toward greater diversity, equity, inclusion, and antiracism in your career or that will be made through your work at Fred Hutch is requested of all finalists.
Our Commitment to Diversity
We are proud to be an Equal Employment Opportunity (EEO) and Vietnam Era Veterans Readjustment Assistance Act (VEVRAA) Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability (physical or mental), marital or veteran status, genetic information, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. If due to a disability you need assistance/and or a reasonable accommodation during the application or recruiting process, please send a request to our Employee Services Center at email@example.com or by calling 206-667-4700.
At Fred Hutchinson Cancer Research Center, teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Researchers are discovering new ways to detect cancers earlier, improve treatments, and learn how to prevent cancers from growing. Although Fred Hutchinson opened its doors in 1975, its history began about 20 years before that. In 1962 Fred Hutchinson envisioned a center devoted to studying cancer, a disease that took his brother’s life. Today Fred Hutchinson is contributing to the next waves of breakthrough treatments and prevention strategies. Fred Hutchinson collaborates with the Seattle Cancer Alliance, the National Cancer Institute, and the University of Washington.